NICE recommends Lilly's Bydureon, but which GLP-agonist will top UK market?
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued limited draft guidance recommending Lilly's GLP1-agonist Bydureon (exenatide extended-release for injectable suspension) for patients with type 2 diabetes. The drug will now compete against other NICE-recommended GLP-1 agonists, the first-in-class Byetta (Lilly's twice daily exenatide) and Novo Nordisk's Victoza (liraglutide), although it is unclear which one will emerge most successful.